Hatteras Venture Partners
Description
Hatteras Venture Partners is a well-established venture capital firm headquartered in Durham, North Carolina, with a singular and deep focus on the life sciences sector. Since its inception in 2000, the firm has been a steadfast supporter of biomedical innovation, channeling capital into companies developing groundbreaking therapeutics, advanced medical devices, sophisticated diagnostics, and transformative digital health solutions. Their strategic location in the Research Triangle Park area positions them at the heart of a thriving biotech ecosystem, allowing them to closely engage with emerging scientific and entrepreneurial talent.
Over more than two decades, Hatteras Venture Partners has successfully raised and deployed significant capital across multiple funds. Their latest vehicle, Hatteras Venture Partners VII, closed in 2023 with $200 million in commitments, underscoring continued investor confidence in their specialized approach. This recent fund brings the firm's total capital under management to approximately $950 million across all seven funds. Hatteras typically targets early-stage companies, often taking a lead or co-lead position in Series A and Series B financing rounds, providing crucial initial capital for product development and clinical trials.
The firm's investment philosophy centers on identifying companies with strong intellectual property, compelling scientific foundations, and experienced management teams capable of navigating the complex regulatory and commercial landscapes of the life sciences. Their initial investment checks typically range from $3 million to $10 million, demonstrating their commitment to providing substantial early-stage funding necessary for capital-intensive biotech ventures. Beyond capital, Hatteras Venture Partners actively supports its portfolio companies with strategic guidance, industry connections, and operational expertise, aiming to accelerate their growth and maximize their potential for impactful innovation and successful exits.
Investor Profile
Hatteras Venture Partners has backed more than 119 startups, with 6 new investments in the last 12 months alone. The firm has led 44 rounds, about 37% of its total and boasts 25 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series A, Series B, Series Unknown rounds (top funding stages).
- Majority of deals are located in United States, Canada.
- Strong thematic focus on Biotechnology, Health Care, Medical.
- Led 4 rounds in the past year.
- Typical check size: $3M – $10M.
Stage Focus
- Series A (39%)
- Series B (24%)
- Series Unknown (13%)
- Series C (13%)
- Seed (6%)
- Series D (2%)
- Private Equity (2%)
- Series E (1%)
- Convertible Note (1%)
Country Focus
- United States (95%)
- Canada (4%)
Industry Focus
- Biotechnology
- Health Care
- Medical
- Medical Device
- Therapeutics
- Pharmaceutical
- Life Science
- Health Diagnostics
- Software
- Clinical Trials
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
